{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:26:30Z","timestamp":1792009590035,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T00:00:00Z","timestamp":1544486400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10157-018-1680-1","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T05:18:29Z","timestamp":1544505509000},"page":"589-596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Changes in serum and intracardiac fibroblast growth factor 23 during the progression of left ventricular hypertrophy in hypertensive model rats"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-1068","authenticated-orcid":false,"given":"Hideki","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,11]]},"reference":[{"key":"1680_CR1","unstructured":"U.S. Renal Data System, USRDS 2016 Annual Data Report. Atlas of chronic kidney disease and end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases."},{"key":"1680_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/kisup.2015.5","volume":"5","author":"N Hanafusa","year":"2015","unstructured":"Hanafusa N, Nakai S, Iseki K, Tsubakihara Y. Japanese society for dialysis therapy renal data registry-a window through which we can view the details of Japanese dialysis population. Kidney Int Suppl. 2015;5:15\u201322.","journal-title":"Kidney Int Suppl"},{"key":"1680_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ki.1995.22","volume":"47","author":"RN Foley","year":"1995","unstructured":"Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186\u201392.","journal-title":"Kidney Int"},{"key":"1680_CR4","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1681\/ASN.V12122759","volume":"12","author":"GM London","year":"2001","unstructured":"London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12:2759\u201367.","journal-title":"J Am Soc Nephrol"},{"key":"1680_CR5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00380-017-0969-4","volume":"32","author":"K Kitamura","year":"2017","unstructured":"Kitamura K, Fujii H, Kono K, Nakai K, Goto S, Nishii T, Kono A, Nishi S. Relationship between cardiac calcification and left ventricular hypertrophy in patients with chronic kidney disease at hemodialysis initiation. Heart Vessels. 2017;32:1109\u201316.","journal-title":"Heart Vessels"},{"key":"1680_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000435838","volume":"5","author":"L Lullo Di","year":"2015","unstructured":"Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med. 2015;5:254\u201366.","journal-title":"Cardiorenal Med"},{"key":"1680_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/ki.2012.176","volume":"82","author":"M Wolf","year":"2012","unstructured":"Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82:737\u201347.","journal-title":"Kidney Int"},{"key":"1680_CR8","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305:2432\u20139.","journal-title":"JAMA"},{"key":"1680_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez OM. Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584\u201392.","journal-title":"N Engl J Med"},{"key":"1680_CR10","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Guti\u00e9rrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305:2432\u20139.","journal-title":"JAMA"},{"key":"1680_CR11","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/bph.13417","volume":"173","author":"H Fujii","year":"2016","unstructured":"Fujii H, Yonekura Y, Yamashita Y, Kono K, Nakai K, Goto S, Sugano M, Goto S, Fujieda A, Ito Y, Nishi S. Anti-oxidative effect of AST-120 on kidney injury after myocardial infarction. Br J Pharmacol. 2016;173:1302\u201313.","journal-title":"Br J Pharmacol"},{"key":"1680_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.bone.2007.10.007","volume":"42","author":"H Fujii","year":"2008","unstructured":"Fujii H, Hamada Y, Fukagawa M. Bone formation in spontaneously diabetic Torii-newly established model of non-obese type 2 diabetes rats. Bone. 2008;42:372\u20139.","journal-title":"Bone"},{"key":"1680_CR13","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","volume":"119","author":"OM Guti\u00e9rrez","year":"2009","unstructured":"Guti\u00e9rrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119:2545\u201352.","journal-title":"Circulation"},{"key":"1680_CR14","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Guti\u00e9rrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro -OM, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Investig. 2011;121:4393\u2013408.","journal-title":"J Clin Investig"},{"key":"1680_CR15","doi-asserted-by":"publisher","first-page":"e73184","DOI":"10.1371\/journal.pone.0073184","volume":"8","author":"K Shibata","year":"2013","unstructured":"Shibata K, Fujita S, Morita H, Okamoto Y, Sohmiya K, Hoshiga M, Ishizaka N. Association between circulating fibroblast growth factor 23, \u03b1-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS ONE. 2013;8:e73184.","journal-title":"PLoS ONE"},{"key":"1680_CR16","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","volume":"22","author":"A Grabner","year":"2015","unstructured":"Grabner A, Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenst\u00e4dt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015;22:1020\u201332.","journal-title":"Cell Metab"},{"key":"1680_CR17","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1097\/HJH.0000000000000936","volume":"34","author":"AL Fyfe-Johnson","year":"2016","unstructured":"Fyfe-Johnson AL, Alonso A, Selvin E, Bower JK, Pankow JS, Agarwal SK, Lutsey PL. Serum fibroblast growth factor-23 and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. J Hypertens. 2016;34:1266\u201372.","journal-title":"J Hypertens"},{"key":"1680_CR18","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/j.1523-1755.2004.66013.x","volume":"66","author":"KR Neves","year":"2004","unstructured":"Neves KR, Graciolli FG, dos Reis LM, Pasqualucci CA, Moys\u00e9s RM, Jorgetti V. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int. 2004;66:2237\u201344.","journal-title":"Kidney Int"},{"key":"1680_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/ki.2012.303","volume":"83","author":"KT Yamamoto","year":"2013","unstructured":"Yamamoto KT, Robinson-Cohen C, de Oliveira MC, Kostina A, Nettleton JA, Ix JH, Nguyen H, Eng J, Lima JA, Siscovick DS, Weiss NS, Kestenbaum B. Dietary phosphorus is associated with greater left ventricular mass. Kidney Int. 2013;83:707\u201314.","journal-title":"Kidney Int"},{"key":"1680_CR20","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.111.032680","volume":"124","author":"S Chen","year":"2011","unstructured":"Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation. 2011;124:1838\u201347.","journal-title":"Circulation"},{"key":"1680_CR21","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.jacc.2008.08.050","volume":"52","author":"JH Lee","year":"2008","unstructured":"Lee JH, O\u2019Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52:1949\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"1680_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3858\/emm.2010.42.1.006","volume":"42","author":"H Cha","year":"2010","unstructured":"Cha H, Jeong HJ, Jang SP, Kim JY, Yang DK, Oh JG, Park WJ. Parathyroid hormone accelerates decompensation following left ventricular hypertrophy. Exp Mol Med. 2010;42:61\u20138.","journal-title":"Exp Mol Med"},{"key":"1680_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2169\/internalmedicine.46.0269","volume":"46","author":"H Fujii","year":"2007","unstructured":"Fujii H, Kim JI, Abe T, Umezu M, Fukagawa M. Relationship between parathyroid hormone and cardiac abnormalities in chronic dialysis patients. Intern Med. 2007;46:1507\u201312.","journal-title":"Intern Med"},{"key":"1680_CR24","first-page":"812","volume":"123","author":"J Voelkl","year":"2013","unstructured":"Voelkl J, Alesutan I, Leibrock CB, Quintanilla-Martinez L, Kuhn V, Feger M, Mia S, Ahmed MS, Rosenblatt KP, Kuro -OM, Lang F. Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Investig. 2013;123:812\u201322.","journal-title":"J Clin Investig"},{"key":"1680_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/01.CIR.0000153800.09920.40","volume":"111","author":"GM Kuster","year":"2005","unstructured":"Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420\u20137.","journal-title":"Circulation"},{"key":"1680_CR26","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1681\/ASN.2013030273","volume":"25","author":"Y Ito","year":"2014","unstructured":"Ito Y, Mizuno M, Suzuki Y, Tamai H, Hiramatsu T, Ohashi H, Ito I, Kasuga H, Horie M, Maruyama S, Yuzawa Y, Matsubara T, Matsuo S, Nagoya Spiro Study Group. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol. 2014;25:1094\u2013102.","journal-title":"J Am Soc Nephrol"},{"key":"1680_CR27","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/ndt\/gfs587","volume":"28","author":"Y Ori","year":"2013","unstructured":"Ori Y, Chagnac A, Korzets A, Zingerman B, Herman-Edelstein M, Bergman M, Gafter U, Salman H. Regression of left ventricular hypertrophy in patients with primary aldosteronism\/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant. 2013;28:1787\u201393.","journal-title":"Nephrol Dial Transplant"},{"key":"1680_CR28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ijcard.2016.07.266","volume":"222","author":"MP Okoshi","year":"2016","unstructured":"Okoshi MP, Cezar MDM, Iyomasa RM, Silva MB, Costa LCO, Martinez PF, Campos DHS, Damatto RL, Minicucci MF, Cicogna AC, Okoshi K. Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. Int J Cardiol. 2016;222:569\u201375.","journal-title":"Int J Cardiol"},{"key":"1680_CR29","doi-asserted-by":"crossref","unstructured":"Leifheit-Nestler M, Kirchhoff F, Nespor J, Richter B, Soetje B, Klintschar M, Heineke J, Haffner D. Fibroblast growth factor 23 is induced by an activated renin\u2013angiotensin\u2013aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts. Nephrol Dial Transplant. 2018 (Epub ahead of print).","DOI":"10.1093\/ndt\/gfy006"},{"key":"1680_CR30","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.bbrc.2016.01.034","volume":"470","author":"B Zhang","year":"2016","unstructured":"Zhang B, Umbach AT, Chen H, Yan J, Fakhri H, Fajol A, Salker MS, Spichtig D, Daryadel A, Wagner CA, F\u00f6ller M, Lang F. Up-regulation of FGF23 release by aldosterone. Biochem Biophys Res Commun. 2016;470:384\u201390.","journal-title":"Biochem Biophys Res Commun"},{"key":"1680_CR31","doi-asserted-by":"publisher","first-page":"11298","DOI":"10.1038\/s41598-017-10140-4","volume":"7","author":"S Slavic","year":"2017","unstructured":"Slavic S, Ford K, Modert M, Becirovic A, Handschuh S, Baierl A, Katica N, Zeitz U, Erben RG, Andrukhova O. Genetic ablation of Fgf23 or klotho does not modulate experimental heart hypertrophy induced by pressure overload. Sci Rep. 2017;7:11298.","journal-title":"Sci Rep"},{"key":"1680_CR32","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/ndt\/gfv421","volume":"31","author":"M Leifhelt-Nestler","year":"2016","unstructured":"Leifhelt-Nestler M, Gro\u00dfe Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler WH, Klintschar M, Becker JU, Erbersdobler A, Aufricht C, Seeman T, Fischer DC, Faul C, Haffner D. Induction of cardiac FGF23\/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31:1088\u201399.","journal-title":"Nephrol Dial Transplant"},{"key":"1680_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.kint.2018.02.018","volume":"94","author":"I Matsui","year":"2018","unstructured":"Matsui I, Oka T, Kusunoki Y, et al. Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23. Kidney Int. 2018;94:60\u201371.","journal-title":"Kidney Int"},{"issue":"5","key":"1680_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","volume":"59","author":"AM Briones","year":"2012","unstructured":"Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59(5):1069\u201378.","journal-title":"Hypertension"},{"issue":"3","key":"1680_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1161\/01.CIR.0000135599.33787.CA","volume":"20","author":"A Mano","year":"2004","unstructured":"Mano A, Tatsumi T, Shiraishi J, et al. Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation. 2004 Jul;20(3):317\u201323. 110(.","journal-title":"Circulation"},{"issue":"6","key":"1680_CR36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/hc0602.104675","volume":"105","author":"Y Takeda","year":"2002","unstructured":"Takeda Y, Yoneda T, Demura M, et al. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation. 2002;105(6):677\u20139.","journal-title":"Circulation"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1680-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1680-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1680-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T23:59:07Z","timestamp":1662595147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1680-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,11]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1680-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,11]]},"assertion":[{"value":"12 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"H.F. received lecture fees from Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Co., Ltd., KISSEI Pharmaceutical Co., Ltd., and ONO Pharmaceutical Co., Ltd., and scholarship\/donation from Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Co., Ltd. and ONO Pharmaceutical Co., Ltd., MSD, Asteras, TEIJIN and KYOWA HAKKO KIRIN Pharmaceutical Co., Ltd. S.N. received lecture fees from Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Co., Ltd., KYOWA HAKKO KIRIN Pharmaceutical Co., and Asteras Pharmaceutical Co., Ltd., and scholarship\/donation from Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Co., Ltd. and ONO Pharmaceutical Co., Ltd., MSD, Asteras, TEIJIN and KYOWA HAKKO KIRIN Pharmaceutical Co., Ltd. All the other authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving animals were in accordance with the ethical standards of the Animal Care and Use Committee of Kobe University (Permit number P160708).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}